Accepted Manuscript

Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival

Miho Kono, MD, Pamela K. Allen, PhD, MPH, Steven H. Lin, MD, PhD, Xiong Wei, MD, Melenda Jeter, MD, MPH, James W. Welsh, MD, James D. Cox, MD, Ritsuko Komaki, MD

PII: S1556-0864(17)30661-5

DOI: 10.1016/j.jtho.2017.07.030

Reference: JTHO 665

To appear in: Journal of Thoracic Oncology

Received Date: 7 March 2017

Revised Date: 13 July 2017

Accepted Date: 26 July 2017

Please cite this article as: Kono M, Allen PK, Lin SH, Wei X, Jeter M, Welsh JW, Cox JD, Komaki R, Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2017.07.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival

Miho Kono, MD,^{1,2} Pamela K. Allen, PhD, MPH,¹ Steven H. Lin, MD, PhD,¹ Xiong Wei, MD,¹ Melenda Jeter, MD, MPH,¹ James W. Welsh, MD,¹ James D. Cox, MD,¹ and Ritsuko Komaki, MD¹

¹Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515

Holcombe Boulevard, Houston, TX 77030, USA

²Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi Minamiku,

Hiroshima, 7348553, Japan

Corresponding author: Ritsuko Komaki, MD, Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston TX 77030 USA. Tel 713-563-2300; FAX 713-563-2331; E-mail rkomaki@mdanderson.org.

Running head: MSM and survival in limited-stage SCLC

Funding: This research was supported in part by Cancer Center Support (Core) Grant CA016672 from the US National Cancer Institute, National Institutes of Health, to The University of Texas MD Anderson Cancer Center.

Conflict of interests: none declared.

Download English Version:

https://daneshyari.com/en/article/8787928

Download Persian Version:

https://daneshyari.com/article/8787928

Daneshyari.com